Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer

Zeng, Linjuan; Li, Jingguo; Wang, Yong; Qian, Changtao; Chen, Yinting; Zhang, Qiubo; Wu, Wei; Zhong, Lin; Liang, Jieying; Shuai, Xintao; Huang, Kaihong

doi:10.1016/j.nano.2013.08.007

Cited by 42 publications

(36 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to PEI, however, it has lower transfection efficiency resulting from endosomal capture [119]. Zeng et al [120] designed two polyethyleneglycol (PEG)-based polymers to deliver siRNA and arsenic trioxide (ATO) to treat pancreatic cancer. PEG-PLL was designed to complex with siRNA and down-regulate mutant Kras gene expression in pancreatic cancer, while PEG-Poly- dl -lactide (PDLLA) was used to encapsulate and deliver ATO into pancreatic cells to induce apoptosis.…”

Section: Polymer-based Nanomaterials For Gene Deliverymentioning

confidence: 99%

“…PEG-PLL was designed to complex with siRNA and down-regulate mutant Kras gene expression in pancreatic cancer, while PEG-Poly- dl -lactide (PDLLA) was used to encapsulate and deliver ATO into pancreatic cells to induce apoptosis. BXPC-3 cell lines with the wild-type Kras allele, and PANC-1 cell lines with a mutant Kras allele were utilized to evaluate the ability to silence the mutant, but not the wild-type Kras allele [120]. The PEG-PLL/siKras system was able to effectively silence the mutant allele, verified at both the mRNA level (a 61% reduction in expression) and the protein level (57% reduction in expression) in PANC-1 cells [120].…”

Section: Polymer-based Nanomaterials For Gene Deliverymentioning

confidence: 99%

“…BXPC-3 cell lines with the wild-type Kras allele, and PANC-1 cell lines with a mutant Kras allele were utilized to evaluate the ability to silence the mutant, but not the wild-type Kras allele [120]. The PEG-PLL/siKras system was able to effectively silence the mutant allele, verified at both the mRNA level (a 61% reduction in expression) and the protein level (57% reduction in expression) in PANC-1 cells [120]. The PEG-PLL/siKras system did not have any silencing effect in the BXPC-3 cells lines, demonstrating the ability to selectively target a specific allele.…”

Section: Polymer-based Nanomaterials For Gene Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Recent Advances in Nanomaterials for Gene Delivery—A Review

2017

View full text Add to dashboard Cite

With the rapid development of nanotechnology in the recent decade, novel DNA and RNA delivery systems for gene therapy have become available that can be used instead of viral vectors. These non-viral vectors can be made of a variety of materials, including inorganic nanoparticles, carbon nanotubes, liposomes, protein and peptide-based nanoparticles, as well as nanoscale polymeric materials. They have as advantages over viral vectors a decreased immune response, and additionally offer flexibility in design, allowing them to be functionalized and targeted to specific sites in a biological system with low cytotoxicity. The focus of this review is to provide an overview of novel nanotechnology-based methods to deliver DNA and small interfering RNAs into biological systems.

show abstract

Section: Polymer-based Nanomaterials For Gene Deliverymentioning

confidence: 99%

Section: Polymer-based Nanomaterials For Gene Deliverymentioning

confidence: 99%

Section: Polymer-based Nanomaterials For Gene Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Nanomaterials for Gene Delivery—A Review

2017

View full text Add to dashboard Cite

show abstract

“…RNAi-based therapies have partial and transient antitumor effects, but when combined with chemotherapy, the result may be more potent and long-lasting [13]. Currently, there are several inhibitors against efflux activity under investigation, in order to sensitize cancer cells to chemotherapy.…”

Section: Combinatory Approachesmentioning

confidence: 99%

Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer—The Case for Combined Delivery?

Mendes

Fernandes

Baptista

2017

Genes

View full text Add to dashboard Cite

Gene therapy arises as a great promise for cancer therapeutics due to its potential to silence genes involved in tumor development. In fact, there are some pivotal gene drivers that suffer critical alterations leading to cell transformation and ultimately to tumor growth. In this vein, gene silencing has been proposed as an active tool to selectively silence these molecular triggers of cancer, thus improving treatment. However, naked nucleic acid (DNA/RNA) sequences are reported to have a short lifetime in the body, promptly degraded by circulating enzymes, which in turn speed up elimination and decrease the therapeutic potential of these drugs. The use of nanoparticles for the effective delivery of these silencers to the specific target locations has allowed researchers to overcome this issue. Particularly, gold nanoparticles (AuNPs) have been used as attractive vehicles for the target-specific delivery of gene-silencing moieties, alone or in combination with other drugs. We shall discuss current trends in AuNP-based delivery of gene-silencing tools, considering the promising road ahead without overlooking existing concerns for their translation to clinics.

show abstract

“…In pre-clinical mouse models, successful targeting of KRAS has been reported. For instance, through systemic administration of nanoparticles containing KRAS-specific small interfering RNA (siRNA), regression of KRAS-driven tumors was observed [52,53]. Several drugs targeting rapidly accelerated fibrosarcoma (RAF)-mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3 kinase), the well-established downstream pathways of KRAS, are being tested in the clinics [54].…”

Section: Molecular Alterations Driving Pancreatic Cancer Progressionmentioning

confidence: 99%

Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward

Khan

Azim

Zubair

et al. 2017

IJMS

View full text Add to dashboard Cite

Pancreatic cancer (PC) continues to rank among the most lethal cancers. The consistent increase in incidence and mortality has made it the seventh leading cause of cancer-associated deaths globally and the third in the United States. The biggest challenge in combating PC is our insufficient understanding of the molecular mechanism(s) underlying its complex biology. Studies during the last several years have helped identify several putative factors and events, both genetic and epigenetic, as well as some deregulated signaling pathways, with implications in PC onset and progression. In this review article, we make an effort to summarize our current understanding of molecular and cellular events involved in the pathogenesis of pancreatic malignancy. Specifically, we provide up-to-date information on the genetic and epigenetic changes that occur during the initiation and progression of PC and their functional involvement in the pathogenic processes. We also discuss the impact of the tumor microenvironment on the molecular landscape of PC and its role in aggressive disease progression. It is envisioned that a better understanding of these molecular factors and the mechanisms of their actions can help unravel novel diagnostic and prognostic biomarkers and can also be exploited for future targeted therapies.

show abstract

Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer

Cited by 42 publications

References 50 publications

Recent Advances in Nanomaterials for Gene Delivery—A Review

Recent Advances in Nanomaterials for Gene Delivery—A Review

Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer—The Case for Combined Delivery?

Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward

Contact Info

Product

Resources

About